Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2002 Nov 12;42(1):19–23. doi: 10.1016/0165-2478(94)90029-9

Expression of aminopeptidase N/CD13 in tumour-infiltrating lymphocytes from human renal cell carcinoma

Dagmar Riemann a,, Barbara Göhring b, Jürgen Langner a
PMCID: PMC7119697  PMID: 7829125

Abstract

We have previously demonstrated the expression of aminopeptidase N (APN, CD13) on synovial T cells from patients with different forms of arthritis. T cells of peripheral blood and serous body fluids are CD13-negative but can be stimulated to express CD13 after activation, e.g., with Con A. In the present report, double-labelling and flow cytometry analyses were performed to characterize the phenotype of tumour-infiltrating lymphocytes (TIL). A large panel of antibodies specific for different activation-associated molecules on T cells was used. In contrast to TIL of lung cancer, TIL of renal cell carcinoma (RCC) consisted of significantly higher percentages of T cells expressing CD13, dipeptidylpeptidase N (DPIV, CD26) and HLA-DR, whereas T cells of lung cancer expressed more CD25, CD69 and CD54/ICAM1. No differences could be found in the expression of CD45RO, CD49a/VLA-1 and CD62L/L-selectin. Our results demonstrate that T cells in RCC and lung cancer differ in their phenotype, especially with respect to surface aminopeptidases. Investigations into the function of APN on T cells could be of help in gaining deeper insight into tumour defence as well as into general mechanisms of T cell functions.

Keywords: Aminopeptidase N, CD13, Renal cell carcinoma, Tumour-infiltrating lymphocytes

Abbreviations: APN, aminopeptidase N; RCC, renal cell carcinoma; DPIV, dipeptidylpeptidase IV; TIL, tumour-infiltrating lymphocytes

References

  • 1.Marguet D., David F., Vivier I., Bernard A.M., Naquet P., Pierres M. Adv. Neuroimmunol. 1993;3:209. [Google Scholar]
  • 2.Fleischer B. Immunol. Today. 1994;15:180. doi: 10.1016/0167-5699(94)90316-6. [DOI] [PubMed] [Google Scholar]
  • 3.Look A.T., Ashmun R.A., Shapiro L.H., Peiper S.C. J. Clin. Invest. 1989;83:1299. doi: 10.1172/JCI114015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lendeckel U., Wex T., Kähne T., Frank K., Reinhold D., Ansorge S. Cell. Immunol. 1994;153:214. doi: 10.1006/cimm.1994.1019. [DOI] [PubMed] [Google Scholar]
  • 5.Kan-Mitchell J., Huang X.Q., Steinman L., Oksenberg J.R., Harel W., Parker J.W., Goedegebuure P.S., Darrow T.L., Mitchell M.S. Cancer Immunol. Immunother. 1993;37:15. doi: 10.1007/BF01516937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Riemann D., Göhring B., Kehlen A., Langner J. Immunobiol. 1993;189:162. [Google Scholar]
  • 7.Dreno B., Bureau B., Stalder J.F., Litoux P. Arch. Dermatol. 1990;126:145. [PubMed] [Google Scholar]
  • 8.Riemann D., Schwachula A., Hentschel M., Langner J. Immunobiol. 1993;187:24. doi: 10.1016/S0171-2985(11)80243-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Riemann D., Wollert H.G., Menschikowski J., Mittenzwei S., Langner J. Int. Arch. Allergy Immunol. 1994;104:48. doi: 10.1159/000236708. [DOI] [PubMed] [Google Scholar]
  • 10.Riemann D., Schwachula A., Langner J. Clin. Rheumatol. 1993;12:31. [Google Scholar]
  • 11.Nakano E., Sonoda T., Fujioka H. Eur. Urol. 1984;10:212. doi: 10.1159/000463791. [DOI] [PubMed] [Google Scholar]
  • 12.Schoof D.D., Terashima Y., Peoples G.E., Goedegebuure P.S., Andrews J.V.R., Richie J.P., Eberlein T.J. Cell Immunol. 1993;150:114. doi: 10.1006/cimm.1993.1183. [DOI] [PubMed] [Google Scholar]
  • 13.Hoon D.S.B., Okun E., Banez M., Irie R.F., Morton D.L. Cancer Res. 1991;51:5687. [PubMed] [Google Scholar]
  • 14.Van Hal P.T., Hopstaken-Broos J.P.M., Wijkhuijs J.M., TeVelde A.A., Figdor C.G., Hoogsteden H.C. J. Immunol. 1992;149:1395. [PubMed] [Google Scholar]
  • 15.Matsas R., Stephenson S.L., Hryszko J., Kenny A.J., Tumer A.J. Biochem. J. 1985;231:445. doi: 10.1042/bj2310445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Stryhn Hansen A., Norén O., Sjöström H., Werdelin O. Eur. J. Immunol. 1993;23:2358. doi: 10.1002/eji.1830230946. [DOI] [PubMed] [Google Scholar]
  • 17.Saiki I., Fujii H., Yoneda J., Abe F., Nakajima M., Tsuruo T., Azuma I. Int. J. Cancer. 1993;54:137. doi: 10.1002/ijc.2910540122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Menrad A., Speicher D., Wacker J., Herlyn M. Cancer Res. 1993;53:1450. [PubMed] [Google Scholar]
  • 19.Delmas B., Gelfi J., L'Haridou R., Vogel L.K., Sjöström H., Norén O., Laude H. Nature. 1992;357:417. doi: 10.1038/357417a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Yeager C.L., Ashmun R.A., Williams R.K., Cardellichio C.B., Shapiro L.H., Look A.T., Holmes K.V. Nature. 1992;357:420. doi: 10.1038/357420a0. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology Letters are provided here courtesy of Elsevier

RESOURCES